Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS)
CNY 12.25
(4.08%)
CNY 12.25
(4.08%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.13 Billion CNY | -25.5% |
| 2022 | 4.21 Billion CNY | 2.17% |
| 2021 | 4.12 Billion CNY | 21.08% |
| 2020 | 3.41 Billion CNY | 3.46% |
| 2019 | 3.29 Billion CNY | 18.35% |
| 2018 | 2.78 Billion CNY | -11.31% |
| 2017 | 3.14 Billion CNY | 31.33% |
| 2016 | 2.39 Billion CNY | 15.36% |
| 2015 | 2.07 Billion CNY | 30.14% |
| 2014 | 1.59 Billion CNY | 12.59% |
| 2013 | 1.41 Billion CNY | 2.54% |
| 2012 | 1.37 Billion CNY | 28.79% |
| 2011 | 1.07 Billion CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.11 Billion CNY | 482.3% |
| 2024 Q2 | 531.64 Million CNY | -52.45% |
| 2024 Q3 | 355.96 Million CNY | -30.94% |
| 2023 Q1 | 1.53 Billion CNY | 70.63% |
| 2023 Q4 | -292.47 Million CNY | -134.56% |
| 2023 Q3 | 846.32 Million CNY | -19.84% |
| 2023 Q2 | 1.05 Billion CNY | -31.17% |
| 2023 FY | 3.14 Billion CNY | -25.5% |
| 2022 Q4 | 898.9 Million CNY | 7.11% |
| 2022 Q2 | 1.47 Billion CNY | 46.97% |
| 2022 Q3 | 839.23 Million CNY | -43.16% |
| 2022 FY | 4.21 Billion CNY | 2.17% |
| 2022 Q1 | 1 Billion CNY | -29.51% |
| 2021 Q1 | 726.89 Million CNY | -55.41% |
| 2021 Q3 | 1.07 Billion CNY | 18.9% |
| 2021 Q4 | 1.42 Billion CNY | 32.66% |
| 2021 FY | 4.12 Billion CNY | 21.08% |
| 2021 Q2 | 903.53 Million CNY | 24.3% |
| 2020 Q2 | 745.38 Million CNY | 19.86% |
| 2020 Q4 | 1.63 Billion CNY | 294.22% |
| 2020 Q1 | 621.89 Million CNY | -47.53% |
| 2020 Q3 | 413.49 Million CNY | -44.53% |
| 2020 FY | 3.41 Billion CNY | 3.46% |
| 2019 FY | 3.29 Billion CNY | 18.35% |
| 2019 Q1 | 789.38 Million CNY | -1.95% |
| 2019 Q2 | 680 Million CNY | -13.86% |
| 2019 Q4 | 1.18 Billion CNY | 84.52% |
| 2019 Q3 | 642.27 Million CNY | -5.55% |
| 2018 FY | 2.78 Billion CNY | -11.31% |
| 2018 Q4 | 805.07 Million CNY | 12.34% |
| 2018 Q3 | 716.65 Million CNY | 9.59% |
| 2018 Q2 | 653.92 Million CNY | 7.21% |
| 2018 Q1 | 609.97 Million CNY | -49.71% |
| 2017 Q1 | 549.53 Million CNY | -41.21% |
| 2017 FY | 3.14 Billion CNY | 31.33% |
| 2017 Q4 | 1.21 Billion CNY | 59.54% |
| 2017 Q3 | 760.33 Million CNY | 23.03% |
| 2017 Q2 | 617.98 Million CNY | 12.46% |
| 2016 FY | 2.39 Billion CNY | 15.36% |
| 2016 Q4 | 934.81 Million CNY | 76.31% |
| 2016 Q3 | 530.22 Million CNY | 2.57% |
| 2016 Q2 | 516.93 Million CNY | 26.2% |
| 2016 Q1 | 409.6 Million CNY | -49.15% |
| 2015 Q1 | 208.74 Million CNY | -68.38% |
| 2015 Q2 | 534.32 Million CNY | 155.97% |
| 2015 FY | 2.07 Billion CNY | 30.14% |
| 2015 Q4 | 805.46 Million CNY | 53.56% |
| 2015 Q3 | 524.53 Million CNY | -1.83% |
| 2014 Q3 | 195.03 Million CNY | -67.23% |
| 2014 FY | 1.59 Billion CNY | 12.59% |
| 2014 Q4 | 660.12 Million CNY | 238.46% |
| 2014 Q2 | 595.15 Million CNY | 317.37% |
| 2014 Q1 | 142.59 Million CNY | 0.0% |
| 2013 FY | 1.41 Billion CNY | 2.54% |
| 2012 FY | 1.37 Billion CNY | 28.79% |
| 2011 FY | 1.07 Billion CNY | 0.0% |